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15-Lipoxygenase-2 has a limited tissue distribution in
epithelial tissues, with mRNA detected in skin,
cornea, lung, and prostate. It was originally cloned
from human hair rootlets. In this study the distribu-
tion of 15-lipoxygenase-2 was characterized in
human skin using immunohistochemistry and in situ
hybridization. Strong uniform 15-lipoxygenase-2
in situ hybridization (n = 6) and immunostaining
(n = 16) were observed in benign cutaneous
sebaceous glands, with expression in differentiated
secretory cells. Strong 15-lipoxygenase-2 immuno-
staining was also observed in secretory cells of
apocrine and eccrine glands. Variable reduced
immunostaining was observed in skin-derived seba-
ceous neoplasms (n = 8). In the eyelid, Meibomian
glands were uniformly negative for 15-lipoxygenase-
2 in all cases examined (n = 9), and sebaceous carci-
nomas apparently derived from Meibomian glands
were also negative (n = 12). The mechanisms
responsible for differential expression in cutaneous
sebaceous vs eyelid Meibomian glands remain to be
established. In epidermis, positive immunostaining
was observed in the basal cell layer in normal skin,
whereas ®ve examined basal cell carcinomas were
negative. Thus, the strongest 15-lipoxygenase-2
expression is in the androgen regulated secretory
cells of sebaceous, apocrine, and eccrine glands. This
compares with the prostate, in which 15-lipoxygen-
ase-2 is expressed in differentiated prostate secretory
cells (and reduced in the majority of prostate adeno-
carcinomas). The product of 15-lipoxygenase-2, 15-
hydroxyeicosatetraenoic acid, may be a ligand for
the nuclear receptor peroxisome proliferator acti-
vated receptor-g, which is expressed in sebocytes,
and contribute to secretory differentiation in andro-
gen regulated tissues such as prostate and sebaceous
glands. Key words: apocrine glands/arachidonic acid/
Meibomian glands/peroxisome proliferator activated recep-
tors. J Invest Dermatol 117:36±43, 2001
T
he recently identi®ed human lipoxygenase, 15-
lipoxygenase-2 (15-LOX-2), has about 35±40%
amino acid sequence identity to the previously
characterized 5-LOX, 12-LOX, and 15-LOX (15-
LOX-1) (Brash et al, 1997) and about 50% identity to
the human 12R-LOX (Boeglin et al, 1998; Sun et al, 1998). 15-
LOX-2 has a limited distribution in epithelial tissues (Brash et al,
1999b): the cDNA was originally cloned from human hair rootlets,
and 15-LOX-2 mRNA was detected in skin, cornea, lung, and
prostate (Brash et al, 1997; Kilty et al, 1999). In contrast to the
previously known human lipoxygenases, 15-LOX-2 was not
identi®ed in peripheral blood leukocytes (Brash et al, 1997). We
have demonstrated that 15-LOX-2 is uniformly expressed in the
differentiated secretory epithelial cells of benign prostate and that
benign prostate synthesizes the 15-LOX-2 metabolite 15S-hydro-
xyeicosatetraeinoic acid (15S-HETE) from arachidonic acid
(Shappell et al, 1999). Furthermore, 15-LOX-2 is substantially or
completely reduced in the majority of prostate adenocarcinomas
(Shappell et al, 1999; Jack et al, 2000).
15-Lipoxygenase is consistently reported as one of the main
lipoxygenase activities in normal human skin (Nugteren and Kivits,
1987; Duell et al, 1988; Baer et al, 1991) and the major activity in
human keratinocytes (Burrall et al, 1985, 1988; Green, 1989). 15-
LOX is also a prominent activity in plucked human hair rootlets
(von Henneicke-von Zepelin et al, 1991; Baer and Green, 1993).
Based on cDNA cloning, the expression of both 15-LOX-1 and
15-LOX-2 is established in skin (Zhao et al, 1995; Brash et al,
1997). These two enzymes are likely to be functionally quite
distinct, with different primary structures, substrate speci®cities and
tissue distributions. 15-LOX-1, discovered originally in reticulo-
cytes, is potentially involved in facilitating cell maturation (Schewe
and KuÈhn, 1991; van Leyen et al, 1998; Brash, 1999), whereas 15-
LOX-2 appears designed to synthesize 15-HETE exclusively,
possibly as a speci®c ligand and signaling molecule (Brash, 1999).
Based on amino acid sequence identities of 78%, it appears that
the structural homolog of 15-LOX-2 in the mouse is an 8-LOX
(Jisaka et al, 1997; Krieg et al, 1998). These two enzymes share
some unique structural aspects, such as a serine residue instead of a
conserved histidine or asparagine in a position close to the iron in
the catalytic domain (Jisaka et al, 1997). The mouse 8-LOX is
known to be inducible in skin by topical application of phorbol
ester (Gschwendt et al, 1986; FuÈrstenberger et al, 1991; Hughes and
Brash, 1991) and is expressed in differentiated keratinocytes (Jisaka
et al, 1997). The product of the mouse 8-LOX, 8-HETE, has been
shown recently to activate peroxisome proliferator-activated
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receptor (PPAR) -a and thereby induce differentiation in murine
keratinocytes (Muga et al, 2000).
In vitro studies utilizing expression vectors indicate that 15-
HETE may be able to activate transcription as a ligand for PPARg
(Nagy et al, 1998). We have recently demonstrated that 15-HETE
activates PPARg-dependent transcription and inhibits proliferation
of prostate carcinoma cell lines (Shappell et al, 2001). Hence, 15-
HETE may represent an endogenous ligand for PPARg in tissues
expressing 15-LOX-2. As 15-LOX-2 has a limited tissue distribu-
tion and was cloned from hair rootlets, in this study we have
investigated its distribution in human skin. Our analysis has
included sebaceous glands, as similar to the prostate, differentiation
of sebocytes is regulated by androgens. Both prostate and sebocytes
express androgen receptor and 5a-reductase, which converts
circulating testosterone to dihydrotestosterone (Thody and
Shuster, 1989; Luu-The et al, 1994; Russell and Wilson, 1994;
Deplewski et al, 1997; Pelletier et al, 1998). Furthermore, PPARg
is expressed in sebaceous glands, and synthetic PPARg agonists can
induce sebocyte differentiation (Rosen®eld et al, 1998). As 15-
LOX-2 expression was reduced in prostate adenocarcinoma
compared with differentiated benign prostate epithelium
(Shappell et al, 1999; Jack et al, 2000), we have also begun
exploring possible altered 15-LOX-2 expression in neoplastic vs
benign sebocytes.
MATERIALS AND METHODS
Case selection Thirty-nine cases from 37 patients were retrieved from
the ®les of the Surgical Pathology and Dermatopathology laboratories of
Vanderbilt University Medical Center. Hematoxylin and eosin slides
were reviewed and cases were selected for the presence of benign
sebaceous, eccrine, and apocrine glands and to achieve a random mixture
of male and female patients of various ages, skin sites, and different
primary disorders for which the original surgical procedure or biopsy was
performed. In addition to skin sebaceous glands, eyelid cases were
selected to provide a source of benign Meibomian glands. There were
14 males and 23 females, with a mean age of 55.6 y (range 2±92) and a
median age of 60 y. Speci®c skin or other sites (known for 35 of 37)
were periorbital/eyelid 21, face (including ears, nose, lips) 11, chest/back
two, and scalp one. Normal adnexa were from cases diagnosed as
``sebaceous hyperplasia'' (n = 3), and from miscellaneous other
conditions, including squamous cell carcinoma or scar from squamous
cell carcinoma or melanoma re-excision (n = 6), basal cell carcinoma
(n = 5), intradermal nevus (n = 1), nevus sebaceous of Jadassohn
(n = 1), ptosis repair (n = 2), and chronic conjunctivitis (n = 1). Benign
and malignant neoplastic sebaceous lesions were selected from a search of
the pathology ®les. Hematoxylin and eosin slides were reviewed and
only cases that met well established criteria for the diagnoses of sebaceous
adenoma (n = 4, from face and back) and sebaceous carcinoma (n = 16)
were included. Sebaceous carcinomas represented lesions arising both
from Meibomian glands (n = 12) and skin sebaceous glands (n = 4).
Immunohistochemistry Paraf®n immunoperoxidase studies were
performed on an automated immunostainer (Ventana ES automated
immunohistochemistry system, Ventana Medical Systems, Tucson, AZ)
with an avidin±biotin method without antigen retrieval techniques. The
rabbit polyclonal anti-human 15-LOX-2 antibody employed was
prepared against puri®ed 15-LOX-2 protein as described (Shappell et al,
1999). Previous western blot studies have shown that this antibody reacts
strongly to 15-LOX-2, without cross-reactivity to 15-LOX-1, 5-LOX,
or platelet type 12-LOX, and with weak cross-reactivity to human 12R-
LOX (Shappell et al, 1999). Immunostaining on paraf®n sections is
eliminated by prior antibody absorption with puri®ed 15-LOX-2 protein
(Shappell et al, 1999). Primary antibody was used at a 1 : 1000 dilution.
Immunostaining in different skin compartments and adnexa is reported
descriptively or semiquantitatively from 0 to 4+: 0, negative; 1+, focal
faint, barely discernible; 2+, moderate intensity in approximately half of
cells/glands; 3+, moderate staining in most cells/glands or strong
immunostaining in approximately 75% of cells/glands; 4+, strong
uniform immunostaining in essentially all cells/glands.
In situ hybridization Discarded human skin tissues were obtained
according to protocols approved by Vanderbilt University Institutional
Review Board. Tissues were immersion-®xed overnight in 4% buffered
paraformaldehyde. Processing for paraf®n embedding and in situ
hybridization were performed as described (Keeney, 1999). [35S]-uridine
triphosphate cRNA were produced by in vitro transcription from a 564
base pair 15-LOX-2 cDNA fragment, prepared from a full length 15-
LOX-2 cDNA in pBluescript SK vector (Stratagene, La Jolla, CA) cut
with EcorV at position 1380 and XhoI at position 1944, generating a
sequence unique to 15-LOX-2 (vs other lipoxygenases) (Brash et al,
1997). Speci®c hybridization was distinguished by comparing silver grain
development produced by sense and anti-sense cRNA applied to
consecutive sections on the same slides. The data presented are
representative results obtained by screening several neonatal foreskins and
breast and abdominal skin samples.
RESULTS
15-LOX-2 immunostaining in benign cutaneous sebaceous
glands, other cutaneous adnexa, and epidermis Strong,
uniform (4+) 15-LOX-2 immunostaining was observed in
essentially all skin sebaceous glands in all cases (n = 16) (Fig 1a±
d). 15-LOX-2 immunostaining in sebaceous glands was noted in
normal sebaceous glands in cases with unrelated lesions, in
sebaceous glands in lesions diagnosed as sebaceous hyperplasia,
and in a nevus sebaceous of Jadassohn. Strong cytoplasmic
immunostaining was noted in differentiated sebaceous cells with
abundant cytoplasm. Some nuclear staining was also noted
(Fig 1d). Immunostaining was generally not detected in
undifferentiated basal cells of sebaceous glands (Fig 1b), with
weak to intermediate staining occasionally noted in ``intermediate''
cells towards the gland lumens, with more cytoplasm, but without
prominent lipid accumulation (cytoplasmic vacuolation) (not
shown). In contrast to the uniform expression of 15-LOX-2 in
differentiated sebocytes, clear cells of the outer hair root sheath
were generally negative (Fig 1b, c, e), but staining was noted in the
inner root sheath/hair matrix in two cases (Fig 1e). The follicular
epidermis was generally negative (Fig 1c).
Positive 15-LOX-2 immunostaining was noted in other cells
with secretory differentiation in other skin adnexa. Generally strong
15-LOX-2 immunostaining was present in apocrine glands,
including those in periorbital tissues (present in nine of nine
cases, 3 or 4+ in 7 and 2+ in 2) (Fig 1e, f). Immunostaining was
noted in the cytoplasm, with staining of lumen secretions and some
nuclei as well. Strong 15-LOX-2 immunostaining was frequently
observed in secretory (luminal) cells of eccrine glands (n = 20, with
3 or 4+ in 10, 2+ in 4, 1+ in 6) (Fig 1g). The nonsecretory clear
cells and myoepithelial cells were negative (Fig 1g).
Compared with the typically strong 15-LOX-2 immunostaining
in secretory cells of sebaceous, apocrine, and eccrine glands, there
was only weak to moderate immunostaining of keratinocytes in the
epidermis in the majority of cases. Staining was generally noted in
the basal cells (1+ in 18, 2+ in 15 cases) (Fig 1h), with focal
staining in keratinocytes in the stratum spinosum in rare cases. In
contrast, the invasive malignant epithelial cells of basal cell
carcinoma were uniformly negative (n = 5) (Fig 2a).
Considering all cases, no 15-LOX-2 immunostaining was noted
in the dermis, dermal in¯ammatory cells, smooth muscle of erector
pili, blood vessels, nevus cells (in a case with an intradermal nevus),
nerves, lacrimal glands (n = 1), retinal epithelium (n = 2), ocular
ciliary body (n = 2), or conjunctiva (n = 2). As expected from the
previous demonstration of 15-LOX-2 mRNA in cornea (Brash
et al, 1997), strong immunostaining was noted in corneal
epithelium (n = 2; not shown).
Possible 15-LOX-2 expression in benign Meibomian glands,
sebaceous adenomas, and sebaceous carcinomas In striking
contrast to the uniform strong 15-LOX-2 immunostaining in skin
sebaceous glands, Meibomian glands of the eyelids were completely
negative for 15-LOX-2 (10 sections from nine different patients)
(Fig 2b, c). In sections with negative Meibomian glands, strong
immunostaining for 15-LOX-2 in adjacent cutaneous adnexa (e.g.,
eccrine or apocrine glands) was present, attesting to preserved
antigenicity in individual tissue sections.
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15-LOX-2 immunostaining was detected in differentiated cells
of four of four cutaneous sebaceous adenomas (Fig 2d); 2+ to 4+
immunostaining was evident in most cells with vacuolated
cytoplasm, with negative staining in basal cells or cells with less
cytoplasm, generally similar to that of benign sebaceous lobules
described above. Immunostaining of a small number of cases of skin
sebaceous carcinoma showed variable, reduced 15-LOX-2 expres-
sion in neoplastic cells (n = 4) (Fig 2e). One case with strong
staining in benign skin sebaceous glands showed markedly reduced
to absent staining in neoplastic cells demonstrating in situ or
Pagetoid spread (not shown). As expected from the lack of 15-
LOX-2 immunostaining in benign Meibomian glands, sebaceous
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carcinomas of the eyelid and apparently arising from Meibomian
glands (n = 12) were generally 15-LOX-2 negative (Fig 2f±h),
with eight cases showing complete lack of immunostaining and
four cases showing either only faint staining or more de®nitive
immunostaining in < 10% of tumor cells.
15-LOX-2 mRNA in sebaceous glands by in situ
hybridization In situ hybridization was used to identify the
cutaneous cell types expressing 15-LOX-2 mRNA and con®rm the
results of immunohistochemistry. 15-LOX-2 was highly expressed
in all sebaceous tissues examined (n = 6) whether from neonatal or
adult skin, or from foreskin, breast, or abdominal locations (Fig 3).
Results obtained from hair follicles sectioned serially indicated that
no parts of the hair root sheath, hair, dermal papillae, follicular
epidermis, or dermis showed hybridization above background
levels. These data con®rm the results showing uniform 15-LOX-2
immunoreactivity in cutaneous sebaceous glands and further
document the speci®city of the antibody employed.
DISCUSSION
In this study, we have demonstrated by immunohistochemistry and
in situ hybridization the strong and uniform expression of 15-LOX-
2 in benign cutaneous sebaceous glands. In situ hydridization is
highly speci®c, being capable of distinguishing mRNA sequences
that differ by 10%; in other words, all transcripts with less than 90%
sequence identity (Keeney, 1999). There are no known human
transcripts with over 50% identity to 15-LOX-2 and, therefore, the
strong positive in situ results are de®nitive. By immunohistochem-
istry, the most obvious and strongest expression of 15-LOX-2 was
in sebaceous glands, which is completely in accord with the in situ
results. Furthermore, based on our substantial experience with the
immunohistochemistry of 15-LOX-2, including correlation with
detection of 15-LOX activity by high-performance liquid
chromatography (Shappell et al, 1999), the negative immunostain-
ing is highly reliable. The signi®cance of weaker 15-LOX-2
immunostaining in basal layers of the epidermis is discussed below.
15-LOX-2 was expressed in differentiated secretory sebocytes.
As in prostate, the differentiation of sebocytes is regulated by
androgens (Thody and Shuster, 1989; Luu-The et al, 1994; Russell
and Wilson, 1994; Deplewski et al, 1997). It has proved dif®cult,
however, to induce sebocyte differentiation with androgens in vitro.
Rosen®eld et al (1998) postulated a connection between androgens
and PPAR receptors. They showed that PPARg mRNA is present
in rat preputial sebocytes and that a synthetic PPARg agonist
induced sebocyte differentiation and that further addition of
dihydrotestosterone had an additive effect (Rosen®eld et al,
1998). In prostate cell lines we have recently demonstrated that
15-HETE activates PPARg-dependent transcription (Shappell et al,
2001). Taken together, these results suggest that 15-HETE may
represent an endogenous ligand for PPARg in 15-LOX-2
expressing tissues, and support a possible correlation of 15-LOX-
2 epithelial expression with androgen regulated secretory tissues.
We also detected 15-LOX-2 immunostaining in eccrine and
apocrine glands, which are also regulated by androgens (Hay and
Hodgins, 1978; Sato et al, 1998). Thus, in addition to a possible
role in sebocyte differentiation, the localization of 15-LOX-2 in
secretory cells of other adnexa (as well as prostatic secretory cells)
suggests a general role in regulating secretory differentiation or
some aspect of the secretory process. As these different cell types
secrete their products by fundamentally different processes, based
on the present evidence we would favor a contribution to cellular
secretory differentiation rather than a participation in the secretion
mechanism per se.
The expression of 15-LOX-2 is known to be reduced in prostate
adenocarcinomas (Shappell et al, 1999; Jack et al, 2000). Perhaps
similarly, the mouse 8-LOX (the 15-LOX-2 homolog), although
upregulated in benign skin squamous papillomas induced by
phorbol esters, is absent in squamous cell carcinomas (Lehmann
et al, 1992; Burger et al, 1999). Therefore, it was of interest to
determine the possibility of changed 15-LOX-2 expression with
the reduced cellular differentiation in sebaceous neoplasms. 15-
LOX-2 immunostaining was present in cells with vacuolated
cytoplasm, correlating with differentiation, in sebaceous adenomas.
Although there was a suggestion of some reduced expression in a
small number of cutaneous sebaceous carcinomas, investigation in a
larger number of the more common Meibomian gland derived
eyelid sebaceous carcinomas revealed the surprising result that
benign Meibomian glands are uniformly negative for 15-LOX-2.
Meibomian glands are modi®ed sebaceous glands, which also
appear to express genes related to androgen processing and
signaling, supporting androgen modulation (Perra et al, 1990;
Sullivan et al, 1998). The reason for this striking difference in 15-
LOX-2 expression between these related tissues remains to be
established. It is possible that tissue speci®c expression of other
genes may be responsible for modulating 15-LOX-2 expression in
androgen sensitive tissues. To the best of our knowledge this
difference in 15-LOX-2 expression in cutaneous sebaceous glands
and Meibomian glands represents the ®rst major biochemical
contrast to be reported. This differential expression could partly
contribute to pathologic conditions with differential predilection
for these two sites, such as acne at cutaneous sites with abundant
15-LOX-2-positive sebaceous glands and the greater frequency of
neoplastic transformation of 15-LOX-2-negative Meibomian
glands.
In comparison with the strong immunostaining for 15-LOX-2 in
sebaceous glands, weaker immunostaining was generally noted in
the epidermis. Immunostaining was seen mainly in the less
differentiated basal layers. This appears to be in contrast to
expression in differentiated secretory cells, such as prostate apical
secretory epithelial cells (Shappell et al, 1999) and sebocytes. Such
basal cell expression was not appreciated in the smaller number of
skin samples analyzed by in situ hybridization. The only known
lipoxygenases that might cross-react with our antibody (see
Materials and Methods) are the 12R-LOX (Boeglin et al, 1998;
Sun et al, 1998) and a third type of epidermal LOX with unknown
positional speci®city (Kinzig et al, 1999); however, by in situ
analysis, the 12R-LOX is expressed in differentiated keratinocytes
and it has low expression in normal skin with no expression in
Figure 1. 15-LOX-2 immunostaining in benign cutaneous adnexa and epidermis. (a) Strong uniform 15-LOX-2 immunostaining in sebaceous
glands (top and center) and eccrine glands (left center) from skin of cheek in 17 y old female. Note negative outer root sheath cells (with clear
cytoplasm) surrounding some weak staining in follicle (bottom left). (b) Typical strong immunostaining in vacuolated cytoplasm of differentiated
sebocytes, with negative surrounding undifferentiated cells. (c) Strong uniform sebaceous gland 15-LOX-2 immunostaining, with negative follicles, in
nevus sebaceous of Jadassohn from scalp of 14 y old male. Note negative outer root sheath adjacent to strongly positive sebaceous lobule, top left. (d)
High magni®cation showing uniform cytoplasmic immunostaining of differentiated sebocytes, with abundant cytoplasmic vacuolization paralleling lipid
accumulation. Possible nuclear staining is noted focally. (e) Uniform 15-LOX-2 immunostaining in apocrine glands (right and bottom) from eyelid of
76 y old female. Note absent staining in outer sheath cells surrounding hair shaft (bottom left) and staining cells within adjacent follicle (top left). (f)
Higher magni®cation showing 15-LOX-2 immunostaining of apocrine glands, including apical ``snouts'' and intraluminal secretion (center), from eyelid
of 70 y old female. (g) 15-LOX-2 immunostaining in luminal secretory cells of eccrine glands, with negative clear cells and outer myoepithelial cells.
Note strong immunostaining of adjacent sebaceous gland (right). (h) 15-LOX-2 immunostaining in basal cells in epidermis, with some (generally
weaker) staining noted focally in suprabasal cells. Note negative papillary dermis. This degree of epidermal staining was stronger than that generally
noted. Scale bars: (a, c) 250 mm; (b, e) 100 mm; (g) 50 mm; (d, f, h) 25 mm.
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sebaceous glands (unpublished results), so this is unlikely to account
for the antigen detected in epidermis by 15-LOX-2 immunostain-
ing or to contribute at all to immunostaining detected in sebaceous
glands. Cross-reaction with the third type of epidermal LOX is
undetermined. Therefore, we consider the current immunohisto-
chemical results showing epidermal expression to be potentially
representative of true 15-LOX-2 expression in epidermis. In the
mouse, expression of the murine homolog 8-LOX increases in
hyperplastic epidermis, being localized particularly in the granular
layer following topical phorbol ester treatment (FuÈrstenberger et al,
1991; Jisaka et al, 1997). The 8-LOX may contribute to
keratinocyte differentiation in the mouse, potentially activating
PPARa by its metabolite 8S-HETE (Muga et al, 2000). As
described above, expression of the 8-LOX is reduced with
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progression to carcinoma (Lehmann et al, 1992). In this regard it is
intriguing that in contrast to the weak to moderate 15-LOX-2
immunostaining in basal layers of benign epidermis, neoplastic cells
of basal cell carcinoma were negative. In general terms, however,
the expression patterns of 15-LOX-2 in human skin and the 8-
LOX in mouse skin are different (Table I). The mouse 8-LOX is
present in differentiated keratinocytes with phorbol ester treatment
and in follicular epithelium; however, it is not seen in sebaceous
glands (unpublished observations), whereas 15-LOX-2 was not
generally expressed in differentiated keratinocytes of the epidermis.
It should be noted, however, that the mouse 8-LOX is only weakly
expressed in normal murine epidermis unless induced by phorbol
ester, a condition that that has not been mimicked in the human.
Future studies will be needed to determine possible increased 15-
LOX-2 expression in benign or reactive epidermal proliferations
and the effects of 15S-HETE on keratinocytes.
Finally, given the strong expression of 15-LOX-2 in sebocytes,
the possibility that its product 15-HETE contributes to other
disease processes of sebaceous glands, such as acne, should be
considered. Results of studies done more than three decades ago
examining the effects of eicosa-5:8:11:14-tetraynoic acid on sebum
production and acne, reinterpreted in light of subsequent know-
ledge of this compound's inhibitory effects on cyclooxygenases and
lipoxygenases, lend in vivo support to this hypothesis. Eicosa-
5:8:11:14-tetraynoic acid, thought to exert its effects on the
inhibition of cholesterol synthesis, resulted in suppression of sebum
production in all subjects tested and an improvement in acne in a
small number of cases examined (Strauss et al, 1967). In subsequent
small trials, topical 2% tetraynoic acid in ethanol appeared to reduce
sebum secretion in acne patients (Burton and Shuster, 1970;
Haroon et al, 1970), whereas similar bene®cial effects were not seen
when topical formulation included 20% propylene glycol in
addition to ethanol (Burton and Shuster, 1972; Haroon et al,
1972). Eicosa-5:8:11:14-tetraynoic acid is well known to be a
nonspeci®c competitive inhibitor of cyclooxygenases and lipox-
ygenases. It inhibits 15-LOX-2, albeit not potently (Kilty et al,
Figure 2. 15-LOX-2 immunostaining in basal cell carcinoma, Meibomian glands, and sebaceous neoplasms. (a) Absent 15-LOX-2 in
invasive nest of basal cell carcinoma (bottom right). Note positive staining in benign sebaceous gland (bottom center) and eccrine glands (top). (b, c)
Completely negative immunostaining in Meibomian glands (from two different cases). Note staining of adjacent apocrine glands in (c). (d) Focal
moderate 15-LOX-2 immunostaining in cells with more vacuolated cytoplasm in a sebaceous adenoma from the face of a 67 y old female. Note
generally absent staining in cells with less cytoplasm. (e) Extensively absent 15-LOX-2 immunostaining in sebaceous carcinoma from eyelid of a 40 y
old white female. Adjacent tissues suggested origin from cutaneous sebaceous glands. Note absent staining in many cells with abundant clear cytoplasm
(bottom and right). Focal strong staining is noted in other portions of the neoplasm (top left). (f) Negative 15-LOX-2 immunostaining in atypical cells
of a sebaceous carcinoma from the left orbit (Meibomian gland derived) of a 92 y old female. (g) Absent 15-LOX-2 immunostaining in poorly
differentiated sebaceous carcinoma from eyelid of 75 y old female. (h) Negative 15-LOX-2 immunostaining in a sebaceous carcinoma (Meibomian
gland derived) invading the orbit of a 70 y old female. Note trabecular bone bottom left. Scale bars: (a±c, e, h) 100 mm; (d, g) 50 mm; (f) 25 mm.
Figure 3. In situ localization of 15S-
lipoxygenase-2 mRNA in human sebocytes.
Neonatal foreskin tissues were sectioned serially
and hybridized with sense and anti-sense
radiolabeled cRNA speci®c for 15-LOX-2. Data
for sense cRNA are not shown. (A, C) Tissue
morphology is shown in bright ®eld. (B, D)
Speci®c hybridization of anti-sense cRNA is
represented by the silver grains visualized in dark-
®eld illumination. Developed silver grains in the
emulsion appear white in dark ®eld and black in
bright ®eld. Silver grains were highly concentrated
in sebaceous glands but not detected above
background levels in other cutaneous cell types.
Scale bar: 400 mM.
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1999). It is thus interesting to speculate that the real mechanism of
reduced sebaceous gland activity by eicosa-5:8:11:14-tetraynoic
acid might be via 15-LOX-2 inhibition and that 15-LOX-2
inhibitors might represent potential novel anti-acne pharmacologic
agents. The recognition of 15-LOX-2- and PPARg-dependent
pathways in androgen-regulated tissues raises important consider-
ations of possible interactions of these signaling mechanisms in
regulating differentiation in 15-LOX-2 expressing tissues.
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